Melanoma: open trials in Norway

• NCT07492680

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  Trial Treatment · Phase 2 · Bristol-Myers Squibb

  Haukeland Universitetssjukehus, Bergen · Oslo universitetssykehus HF, Ullevål, Oslo

  Registry updated 2026-11-04

• NCT06172478

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  Trial Treatment · Phase 2 · Daiichi Sankyo

  Akershus universitetssykehus, Lørenskog · Haukeland universitetssjukehus, Lørenskog · Oslo Universitetssykehus HF, Radiumhospitalet, Oslo

  Registry updated 2026-10-26

• NCT03340129

  Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

  Trial Treatment · Phase 2 · Melanoma Institute Australia

  Oslo Univesity Hospital Radiumhospitalet, Oslo

  Registry updated 2026-10-08

• NCT06697301

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  Trial Treatment · Phase 2/3 · Eikon Therapeutics

  Nordlandssykehuset HF, Bodo · Vestre Viken HF, Drammen · Oslo University Hospital HF, Oslo

  Registry updated 2026-10-06

• NCT06246149

  Adjuvant Tebentafusp in High Risk Ocular Melanoma

  Trial Treatment · Phase 3 · European Organisation for Research and Treatment of Cancer - EORTC

  Oslo Universitetssykehus HF, Oslo

  Registry updated 2026-06-30

• 2023-508156-20-00

  A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial.

  Trial Treatment · Phase 3 · Vaestra Goetalandsregionen

  Oslo Universitetssykehus HF, Oslo

  Registry updated 2026-04-27

• NCT06488482

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  Trial Treatment · Phase 3 · Uppsala University

  Helse Moere Og Romsdal HF, Aalesund · Helse Bergen HF, Bergen · Vestre Viken HF, Drammen · Sorlandet Sykehus HF, Kristiansand S · Akershus University Hospital, Lorenskog · Oslo University Hospital HF, Oslo · Helse Stavanger HF, Stavanger · Sykehuset I Vestfold HF, Toensberg · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim

  Registry updated 2026-03-09

• NCT06112314

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  Trial Treatment · Phase 3 · Immunocore Ltd

  Haukeland University Hospital, Bergen · Oslo University Hospital, Oslo

  Registry updated 2026-02-25

• NCT06651151

  NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

  Trial Treatment · Phase 2 · Oslo University Hospital

  Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo

  Registry updated 2024-10-26

All Melanoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error